| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2011101409 |
| Title |
Pyrrolopyrimidine Compounds As Inhibitors of Cdk4/6. |
| Abstract |
The invention is directed to novel pyrrolopyrimidine compounds of formula (I) wherein R1, R2Y, R4, R8- R11, A and L are defined herein and to salts, including pharmaceutically acceptable salts thereof. The compounds of the present invention are CDK4/6 inhibitors and could be useful in the treatment of diseases and disorders mediated by CDK4/6, such as cancer, including mantle cell lymphoma, liposarcoma, non small cell lung cancer, melanoma, squamous cell esophageal cancer and breast cancer. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CDK4/6 activity and to the treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. |
| Applicant(s) |
Novartis Ag |
| Representative Drug(s) |
D04AKA |
Drug Info
|
IC50 = 3 nM |
[1] |
| Patent ID |
WO2010125402 |
| Title |
Imidazole Derivatives and Their Use As Modulators of Cyclin Dependent Kinases. |
| Abstract |
The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+-O- or CR3; Y is N, N+-O- or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers. |
| Applicant(s) |
Novartis Ag |
| Representative Drug(s) |
D0WT7D |
Drug Info
|
IC50 = 3 nM |
[1] |
| Patent ID |
WO2010075542 |
| Title |
Cdk Inhibitors. |
| Abstract |
The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. |
| Applicant(s) |
Curis, Inc |
| Representative Drug(s) |
D0M5DX |
Drug Info
|
IC50 < 100 nM |
[1] |
| Patent ID |
WO2010069833 |
| Title |
Pyrimidin- 2 -Ylamino Derivatives and Their Use To Treat Inflammation. |
| Abstract |
Compounds of formula (I) modulate JNK wherein X1 and X2 are each simultaneously N or CH; X3 is CH-R2 or N-SO2R, where R is lower alkyl; R1 is aryl or heteroaryl, substituted with 0-3 lower alkyl radicals; R2 is formula (II), where R3 is H, lower acyl, or an amino acid, or a pharmaceutically acceptable salt thereof. |
| Applicant(s) |
F. Hoffmann-La Roche Ag |
| Representative Drug(s) |
D0H4HD |
Drug Info
|
IC50 = 910 nM |
[2] |
| Patent ID |
WO2010020675 |
| Title |
Pyrrolopyrimidine Compounds As Cdk Inhibitors. |
| Abstract |
The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein. |
| Applicant(s) |
Novartis Ag |
| Representative Drug(s) |
D08KKC |
Drug Info
|
IC50 < 1 nM |
[1] |
| Patent ID |
WO2009085185 |
| Title |
Fused Pyridine, Pyrimidine and Triazine Compounds As Cell Cycle Inhibitors. |
| Abstract |
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives. |
| Applicant(s) |
Amgen, Inc |
| Patent ID |
WO2009036016 |
| Title |
Cdk Inhibitors Containing A Zinc Binding Moiety. |
| Abstract |
The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors. |
| Applicant(s) |
Curis, Inc |
| Representative Drug(s) |
D0M5DX |
Drug Info
|
IC50 < 100 nM |
[1] |
| Patent ID |
WO2008028860 |
| Title |
Benzotriazole Kinase Modulators. |
| Abstract |
The invention is concerned with novel benzotriazole derivatives of Formula (I) Wherein R, R1, R2, R3, and m are as defined in the description and the claims, as well as physiologically acceptable salts thereof. These compounds are JNK and CDK modulators. |
| Applicant(s) |
F. Hoffmann-La Roche Ag |
| Representative Drug(s) |
D0H4HD |
Drug Info
|
IC50 = 910 nM |
[2] |
| Patent ID |
WO2014144326 |
| Title |
Transient Protection of Normal Cells During Chemotherapy. |
| Abstract |
This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders. |
| Applicant(s) |
G1 Therapeutics, Inc |
| Representative Drug(s) |
D03HED |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014089450 |
| Title |
Specific Inhibitors of Cdk3. |
| Abstract |
The invention provides new compounds and methods for inhibiting Cyclin-Dependent Kinase 3 (CDK3), and new methods for identifying such compounds. |
| Applicant(s) |
Senex Biotechnology, Inc |
| Representative Drug(s) |
D0FQ6V |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012061156 |
| Title |
Cdk Inhibitors. |
| Abstract |
Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors. |
| Applicant(s) |
G1 Therapeutics, Inc |
| Representative Drug(s) |
D03HED |
Drug Info
|
N.A. |
[1] |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US20107713994 |
| Title |
Anticancer Activity of Cyclin Dependent Kinase Inhibitors. |
| Representative Drug(s) |
D0W4MN |
Drug Info
|
IC50 = 4 nM |
[1] |
| Canadian Intellectual Property Office (CIPO) |
| Patent ID |
CA2597193 |
| Title |
Compounds and Uses. |
| Representative Drug(s) |
D0LX6X |
Drug Info
|
N.A. |
[1] |
